Oncolytic Virus Immunotherapy Market is segmented by Melanoma, Hospitals, Bladder Cancer, Colorectal Cancer, Breast Cancer
Industry: Healthcare
Published Date: October-2019
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 119
Report ID: PMRREP15262
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Inclusions
4.1. Product Adoption / Usage Analysis
4.2. Product USPs / Features
4.3. Establishing Industry - Institutional Partnerships
4.4. Identifying Unique Delivery Methods for Oncolytic Virus Therapy
5. Global Oncolytic Virus Immunotherapy Market Demand (in Value or Size in US$ Mn) Analysis 2015-2018 and Forecast, 2019-2029
5.1. Historical Market Value (US$ Mn) Analysis, 2015-2018
5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
6. Market Background
6.1. Macro-Economic Factors
6.1.1. Global GDP Growth Outlook
6.1.2. Global Healthcare Industry Outlook
6.2. Forecast Factors - Relevance & Impact
6.2.1. Adoption of Oncolytic Virus Immunotherapy
6.2.2. Ongoing Clinical Trials
6.2.3. Regulatory Imposition on Oncolytic Virus Immunotherapy
6.2.4. Advancements in Oncolytic Virus Immunotherapy
6.2.5. Incremental R&D by Product-Based Companies
6.3. Regulatory Scenario for GMP
6.4. Value Chain
6.5. Market Dynamics
6.5.1. Drivers
6.5.2. Restraints
6.5.3. Opportunity Analysis
7. Global Oncolytic Virus Immunotherapy Market - Venture Capital Financing
8. Global Oncolytic Virus Immunotherapy Market -Pipeline Analysis
9. Global Oncolytic Virus Immunotherapy Market Analysis 2015-2018 and Forecast 2019-2029, by Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Indication, 2014 - 2018
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2019 - 2029
9.3.1. Melanoma
9.4. Market Attractiveness Analysis By Indication
10. Global Oncolytic Virus Immunotherapy Market Analysis 2015-2018 and Forecast 2019-2029, By End User
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By End User, 2014 - 2018
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2019 - 2029
10.3.1. Hospitals
10.3.2. Specialty Clinics
10.3.3. Cancer Research Institutes
10.4. Market Attractiveness Analysis By End User
11. Global Oncolytic Virus Immunotherapy Market Analysis 2015-2018 and Forecast 2019-2029, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2014 - 2018
11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019 - 2029
11.3.1. North America
11.3.2. Europe
11.4. Market Attractiveness Analysis By Region
12. Competition Analysis
12.1. Competition Dashboard
12.2. Competition Deep Dive
12.2.1. BioVex, Inc. (Amgen, Inc.)
12.2.1.1. Overview
12.2.1.2. Product Portfolio
12.2.1.3. Profitability by Market Segments (Product/Channel/Region)
12.2.1.4. Sales Footprint
12.2.1.5. Strategy Overview
12.2.1.5.1. Marketing Strategy
12.2.1.5.2. Product Strategy
12.2.1.5.3. Channel Strategy
12.2.2. Cold Genesys, Inc.
12.2.2.1. Overview
12.2.2.2. Product Portfolio
12.2.2.3. Profitability by Market Segments (Product/Channel/Region)
12.2.2.4. Sales Footprint
12.2.2.5. Strategy Overview
12.2.2.5.1. Marketing Strategy
12.2.2.5.2. Product Strategy
12.2.2.5.3. Channel Strategy
12.2.3. DNAtrix Therapeutics
12.2.3.1. Overview
12.2.3.2. Product Portfolio
12.2.3.3. Profitability by Market Segments (Product/Channel/Region)
12.2.3.4. Sales Footprint
12.2.3.5. Strategy Overview
12.2.3.5.1. Marketing Strategy
12.2.3.5.2. Product Strategy
12.2.3.5.3. Channel Strategy
12.2.4. Genelux Corporation
12.2.4.1. Overview
12.2.4.2. Product Portfolio
12.2.4.3. Profitability by Market Segments (Product/Channel/Region)
12.2.4.4. Sales Footprint
12.2.4.5. Strategy Overview
12.2.4.5.1. Marketing Strategy
12.2.4.5.2. Product Strategy
12.2.4.5.3. Channel Strategy
12.2.5. Lokon Pharma AB
12.2.5.1. Overview
12.2.5.2. Product Portfolio
12.2.5.3. Profitability by Market Segments (Product/Channel/Region)
12.2.5.4. Sales Footprint
12.2.5.5. Strategy Overview
12.2.5.5.1. Marketing Strategy
12.2.5.5.2. Product Strategy
12.2.5.5.3. Channel Strategy
12.2.6. Oncolytics Biotech, Inc.
12.2.6.1. Overview
12.2.6.2. Product Portfolio
12.2.6.3. Profitability by Market Segments (Product/Channel/Region)
12.2.6.4. Sales Footprint
12.2.6.5. Strategy Overview
12.2.6.5.1. Marketing Strategy
12.2.6.5.2. Product Strategy
12.2.6.5.3. Channel Strategy
12.2.7. ORYX GmbH & Co. KG
12.2.7.1. Overview
12.2.7.2. Product Portfolio
12.2.7.3. Profitability by Market Segments (Product/Channel/Region)
12.2.7.4. Sales Footprint
12.2.7.5. Strategy Overview
12.2.7.5.1. Marketing Strategy
12.2.7.5.2. Product Strategy
12.2.7.5.3. Channel Strategy
12.2.8. PsiOxus Therapeutics
12.2.8.1. Overview
12.2.8.2. Product Portfolio
12.2.8.3. Profitability by Market Segments (Product/Channel/Region)
12.2.8.4. Sales Footprint
12.2.8.5. Strategy Overview
12.2.8.5.1. Marketing Strategy
12.2.8.5.2. Product Strategy
12.2.8.5.3. Channel Strategy
12.2.9. SillaJen, Inc.
12.2.9.1. Overview
12.2.9.2. Product Portfolio
12.2.9.3. Profitability by Market Segments (Product/Channel/Region)
12.2.9.4. Sales Footprint
12.2.9.5. Strategy Overview
12.2.9.5.1. Marketing Strategy
12.2.9.5.2. Product Strategy
12.2.9.5.3. Channel Strategy
12.2.10. Sorrento Therapeutics, Inc.
12.2.10.1. Overview
12.2.10.2. Product Portfolio
12.2.10.3. Profitability by Market Segments (Product/Channel/Region)
12.2.10.4. Sales Footprint
12.2.10.5. Strategy Overview
12.2.10.5.1. Marketing Strategy
12.2.10.5.2. Product Strategy
12.2.10.5.3. Channel Strategy
12.2.11. Takara Bio
12.2.11.1. Overview
12.2.11.2. Product Portfolio
12.2.11.3. Profitability by Market Segments (Product/Channel/Region)
12.2.11.4. Sales Footprint
12.2.11.5. Strategy Overview
12.2.11.5.1. Marketing Strategy
12.2.11.5.2. Product Strategy
12.2.11.5.3. Channel Strategy
12.2.12. Targovax ASA
12.2.12.1. Overview
12.2.12.2. Product Portfolio
12.2.12.3. Profitability by Market Segments (Product/Channel/Region)
12.2.12.4. Sales Footprint
12.2.12.5. Strategy Overview
12.2.12.5.1. Marketing Strategy
12.2.12.5.2. Product Strategy
12.2.12.5.3. Channel Strategy
12.2.13. Transgene sa
12.2.13.1. Overview
12.2.13.2. Product Portfolio
12.2.13.3. Profitability by Market Segments (Product/Channel/Region)
12.2.13.4. Sales Footprint
12.2.13.5. Strategy Overview
12.2.13.5.1. Marketing Strategy
12.2.13.5.2. Product Strategy
12.2.13.5.3. Channel Strategy
12.2.14. Turnstone Biologics
12.2.14.1. Overview
12.2.14.2. Product Portfolio
12.2.14.3. Profitability by Market Segments (Product/Channel/Region)
12.2.14.4. Sales Footprint
12.2.14.5. Strategy Overview
12.2.14.5.1. Marketing Strategy
12.2.14.5.2. Product Strategy
12.2.14.5.3. Channel Strategy
12.2.15. VCN Biosciences
12.2.15.1. Overview
12.2.15.2. Product Portfolio
12.2.15.3. Profitability by Market Segments (Product/Channel/Region)
12.2.15.4. Sales Footprint
12.2.15.5. Strategy Overview
12.2.15.5.1. Marketing Strategy
12.2.15.5.2. Product Strategy
12.2.15.5.3. Channel Strategy
12.2.16. Viralytics Ltd. (Merck & Co., Inc.)
12.2.16.1. Overview
12.2.16.2. Product Portfolio
12.2.16.3. Profitability by Market Segments (Product/Channel/Region)
12.2.16.4. Sales Footprint
12.2.16.5. Strategy Overview
12.2.16.5.1. Marketing Strategy
12.2.16.5.2. Product Strategy
12.2.16.5.3. Channel Strategy
12.2.17. Vyriad
12.2.17.1. Overview
12.2.17.2. Product Portfolio
12.2.17.3. Profitability by Market Segments (Product/Channel/Region)
12.2.17.4. Sales Footprint
12.2.17.5. Strategy Overview
12.2.17.5.1. Marketing Strategy
12.2.17.5.2. Product Strategy
12.2.17.5.3. Channel Strategy
12.2.18. Shanghai Sunway Biotech
12.2.18.1. Overview
12.2.18.2. Product Portfolio
12.2.18.3. Profitability by Market Segments (Product/Channel/Region)
12.2.18.4. Sales Footprint
12.2.18.5. Strategy Overview
12.2.18.5.1. Marketing Strategy
12.2.18.5.2. Product Strategy
12.2.18.5.3. Channel Strategy
13. Assumptions and Acronyms Used
14. Research Methodology
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Table 01: Prevalence of Cancer in North America, 2017
Table 02: Prevalence of Cancer in Latin America, 2017
Table 03: Prevalence of Cancer in Asia Pacific, 2017
Table 04: Prevalence of Cancer in Europe, 2017
Table 05: Number of FDA Approvals (2010-2017)
Table 06: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 07: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 08: Funding by Research Areas 2017 (US $Millions)
Table 09: Funding by Research Areas 2017 (US $Millions)
Table 10: Estimated Number of Deaths for the Four Major Cancers by Sex and Age Group, 2017
Table 11: Global Oncolytic Virus Immunotherapy Market Deals and Collaborations (1/2)
Table 12: Global Oncolytic Virus Immunotherapy Market Deals and Collaborations (2/2)
Table 13: Oncolytic Virus Immunotherapy Market Top Oncolytic Virus Projects (1/2)
Table 14: Oncolytic Virus Immunotherapy Market Top Oncolytic Virus Projects (2/2)
Table 15: Oncolytic Virus Immunotherapy Market Top Oncolytic Virus Projects (3/3)
Table 16: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (1/7)
Table 17: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (2/7)
Table 18: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (3/7)
Table 19: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (4/7)
Table 20: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (5/7)
Table 21: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (6/7)
Table 22: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (7/7)
Table 23: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Analysis 2015-2018 and Forecast 2019-2029, By End User
Table 24: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Analysis 2015-2018 and Forecast 2019-2029, By Region
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Figure 01: Global Oncolytic Virus Immunotherapy Market Value Share By Indications (2019 E)
Figure 02: Global Oncolytic Virus Immunotherapy Market Value Share By End User (2019 E)
Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share By Regions (2019 E)
Figure 04: Number of FDA approved pharmaceuticals (2010-2017)
Figure 05: Global Healthcare Expenditure in US$ Tn (2013-2020)
Figure 06: New Cancer Drugs Approved Each Year
Figure 07: Estimates of National Expenditures for Cancer Care (In Billions Of Dollars) by Cancer Site and Year
Figure 08: Distribution of Industry sponsored Pipeline Projects for Oncolytic Virus Immunotherapy, by Indication
Figure 09: Distribution of Industry sponsored Pipeline Projects for Oncolytic Virus Immunotherapy By Phase
Figure 10: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Opportunity Assessment 2019-2029 (Optimistic Scenario)
Figure 11: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Opportunity Assessment 2019-2029 (Conservative Scenario)
Figure 12: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Opportunity Assessment 2019-2029 (Likely Scenario)
Figure 13: Global Oncolytic Virus Immunotherapy Market Value Analysis (US$ Mn), 2015-2018
Figure 14: Global Oncolytic Virus Immunotherapy Market Value Analysis (US$ Mn), 2019-2029
Figure 15: Global Oncolytic Virus Immunotherapy Market Absolute $ Opportunity, 2015-2018
Figure 16: Global Oncolytic Virus Immunotherapy Market Absolute $ Opportunity, 2019-2029
Figure 17: Global Oncolytic Virus Immunotherapy Market Analysis By End User -2019 & 2029
Figure 18: Global Oncolytic Virus Immunotherapy Market Y-o-Y Growth Projections by End User, 2019-2029
Figure 19: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, By End User
Figure 20: Global Oncolytic Virus Immunotherapy Market Share Analysis (%) By Region, 2019 & 2029
Figure 21: Global Oncolytic Virus Immunotherapy Market Y-o-Y Growth (%) By Region, 2019-2029
Figure 22: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, By Region
